Second-Line Therapy for RAS Wild-Type mCRC

Cetuximab with XELOX or XELIRI is tolerable and effective in RAS wild-type mCRCПодробнее

Expert Report on panitumumab for first line treatment of RAS wild type mCRC from ASCO 2022Подробнее

Role of anti EGFR in mCRC - Beyond first line | Dr. Viraj Lavingia - Program OrganizerПодробнее

Second-Line RAS Wild-Type Metastatic Colorectal CancerПодробнее

Virtual Meet on Anti-EGFR in mCRC || Sunday, 23 May 2021Подробнее

Choosing Between VEGF and EGFR Targeted Therapy in mCRCПодробнее

Second-Line Treatment Options in Metastatic Colorectal CancerПодробнее

Frontline Decisions in RAS Wild-Type Left-Sided mCRCПодробнее

Second-Line Therapy for RAS Wild-Type mCRCПодробнее